Cargando…
Recommended Immunological Strategies to Screen for Botulinum Neurotoxin-Containing Samples
Botulinum neurotoxins (BoNTs) cause the life-threatening neurological illness botulism in humans and animals and are divided into seven serotypes (BoNT/A–G), of which serotypes A, B, E, and F cause the disease in humans. BoNTs are classified as “category A” bioterrorism threat agents and are relevan...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4690110/ https://www.ncbi.nlm.nih.gov/pubmed/26703727 http://dx.doi.org/10.3390/toxins7124860 |
_version_ | 1782406956602884096 |
---|---|
author | Simon, Stéphanie Fiebig, Uwe Liu, Yvonne Tierney, Rob Dano, Julie Worbs, Sylvia Endermann, Tanja Nevers, Marie-Claire Volland, Hervé Sesardic, Dorothea Dorner, Martin B. |
author_facet | Simon, Stéphanie Fiebig, Uwe Liu, Yvonne Tierney, Rob Dano, Julie Worbs, Sylvia Endermann, Tanja Nevers, Marie-Claire Volland, Hervé Sesardic, Dorothea Dorner, Martin B. |
author_sort | Simon, Stéphanie |
collection | PubMed |
description | Botulinum neurotoxins (BoNTs) cause the life-threatening neurological illness botulism in humans and animals and are divided into seven serotypes (BoNT/A–G), of which serotypes A, B, E, and F cause the disease in humans. BoNTs are classified as “category A” bioterrorism threat agents and are relevant in the context of the Biological Weapons Convention. An international proficiency test (PT) was conducted to evaluate detection, quantification and discrimination capabilities of 23 expert laboratories from the health, food and security areas. Here we describe three immunological strategies that proved to be successful for the detection and quantification of BoNT/A, B, and E considering the restricted sample volume (1 mL) distributed. To analyze the samples qualitatively and quantitatively, the first strategy was based on sensitive immunoenzymatic and immunochromatographic assays for fast qualitative and quantitative analyses. In the second approach, a bead-based suspension array was used for screening followed by conventional ELISA for quantification. In the third approach, an ELISA plate format assay was used for serotype specific immunodetection of BoNT-cleaved substrates, detecting the activity of the light chain, rather than the toxin protein. The results provide guidance for further steps in quality assurance and highlight problems to address in the future. |
format | Online Article Text |
id | pubmed-4690110 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-46901102015-12-30 Recommended Immunological Strategies to Screen for Botulinum Neurotoxin-Containing Samples Simon, Stéphanie Fiebig, Uwe Liu, Yvonne Tierney, Rob Dano, Julie Worbs, Sylvia Endermann, Tanja Nevers, Marie-Claire Volland, Hervé Sesardic, Dorothea Dorner, Martin B. Toxins (Basel) Article Botulinum neurotoxins (BoNTs) cause the life-threatening neurological illness botulism in humans and animals and are divided into seven serotypes (BoNT/A–G), of which serotypes A, B, E, and F cause the disease in humans. BoNTs are classified as “category A” bioterrorism threat agents and are relevant in the context of the Biological Weapons Convention. An international proficiency test (PT) was conducted to evaluate detection, quantification and discrimination capabilities of 23 expert laboratories from the health, food and security areas. Here we describe three immunological strategies that proved to be successful for the detection and quantification of BoNT/A, B, and E considering the restricted sample volume (1 mL) distributed. To analyze the samples qualitatively and quantitatively, the first strategy was based on sensitive immunoenzymatic and immunochromatographic assays for fast qualitative and quantitative analyses. In the second approach, a bead-based suspension array was used for screening followed by conventional ELISA for quantification. In the third approach, an ELISA plate format assay was used for serotype specific immunodetection of BoNT-cleaved substrates, detecting the activity of the light chain, rather than the toxin protein. The results provide guidance for further steps in quality assurance and highlight problems to address in the future. MDPI 2015-11-26 /pmc/articles/PMC4690110/ /pubmed/26703727 http://dx.doi.org/10.3390/toxins7124860 Text en © 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Simon, Stéphanie Fiebig, Uwe Liu, Yvonne Tierney, Rob Dano, Julie Worbs, Sylvia Endermann, Tanja Nevers, Marie-Claire Volland, Hervé Sesardic, Dorothea Dorner, Martin B. Recommended Immunological Strategies to Screen for Botulinum Neurotoxin-Containing Samples |
title | Recommended Immunological Strategies to Screen for Botulinum Neurotoxin-Containing Samples |
title_full | Recommended Immunological Strategies to Screen for Botulinum Neurotoxin-Containing Samples |
title_fullStr | Recommended Immunological Strategies to Screen for Botulinum Neurotoxin-Containing Samples |
title_full_unstemmed | Recommended Immunological Strategies to Screen for Botulinum Neurotoxin-Containing Samples |
title_short | Recommended Immunological Strategies to Screen for Botulinum Neurotoxin-Containing Samples |
title_sort | recommended immunological strategies to screen for botulinum neurotoxin-containing samples |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4690110/ https://www.ncbi.nlm.nih.gov/pubmed/26703727 http://dx.doi.org/10.3390/toxins7124860 |
work_keys_str_mv | AT simonstephanie recommendedimmunologicalstrategiestoscreenforbotulinumneurotoxincontainingsamples AT fiebiguwe recommendedimmunologicalstrategiestoscreenforbotulinumneurotoxincontainingsamples AT liuyvonne recommendedimmunologicalstrategiestoscreenforbotulinumneurotoxincontainingsamples AT tierneyrob recommendedimmunologicalstrategiestoscreenforbotulinumneurotoxincontainingsamples AT danojulie recommendedimmunologicalstrategiestoscreenforbotulinumneurotoxincontainingsamples AT worbssylvia recommendedimmunologicalstrategiestoscreenforbotulinumneurotoxincontainingsamples AT endermanntanja recommendedimmunologicalstrategiestoscreenforbotulinumneurotoxincontainingsamples AT neversmarieclaire recommendedimmunologicalstrategiestoscreenforbotulinumneurotoxincontainingsamples AT vollandherve recommendedimmunologicalstrategiestoscreenforbotulinumneurotoxincontainingsamples AT sesardicdorothea recommendedimmunologicalstrategiestoscreenforbotulinumneurotoxincontainingsamples AT dornermartinb recommendedimmunologicalstrategiestoscreenforbotulinumneurotoxincontainingsamples |